|
Patent landscape, scope, and claims: |
Analysis of Patent 4,382,090: Scope, Claims, and Patent Landscape
What is the Scope of Patent 4,382,090?
Patent 4,382,090, issued on May 3, 1983, covers a formulation of a pharmaceutical composition that notably includes erythromycin and a carrier suitable for oral administration. It claims a specific combination designed to improve oral bioavailability of erythromycin by utilizing a particular formulation method.
The patent's primary scope encompasses:
- A pharmaceutical composition comprising erythromycin or its derivatives.
- Use of specific carriers such as fatty acids, esters, or fatty acid derivatives that improve dissolution and absorption.
- A formulation process that enhances stability and bioavailability.
- Dosage forms, including tablets and capsules, with specified excipients and coating techniques.
The scope explicitly excludes formulations not using the claimed carriers or different manufacturing methods. It does not cover erythromycin in non-oral forms or other macrolide antibiotics outside the scope of the described composition.
What are the Key Claims of Patent 4,382,090?
The patent's claims are centered around the composition and manufacturing methods. The strongest claims are:
-
Claim 1: A pharmaceutical composition comprising erythromycin, a fatty acid ester carrier (such as ethyl oleate), and a pharmaceutically acceptable carrier capable of enhancing absorption.
-
Claim 2: The composition from claim 1, wherein the carrier is an ester of fatty acids with a specified chain length (e.g., C14-C22).
-
Claim 3: A method of producing the composition involving dissolving erythromycin in the carrier to produce a stable formulation suitable for oral administration.
-
Claim 4: The composition claimed in claim 1, further coated with a semi-permeable membrane to control release.
The claims concentrate on both the composition itself and the manufacturing process, emphasizing the use of fatty acid esters as carriers that enhance erythromycin absorption.
Claim scope analysis:
- The formulation claims are broad enough to cover various fatty acid esters, particularly ethyl oleate.
- Limited by specific carrier types and manufacturing steps.
- The claims do not extend to other macrolide antibiotics or non-oral delivery systems.
How Does Patent 4,382,090 Fit Into the Broader Patent Landscape?
The patent was filed in 1981 and issued in 1983 under the U.S. Patent and Trademark Office (USPTO). Its expiration date is 2000, assuming maintenance fees were paid. It sits within the broader landscape of macrolide formulations with early innovations in improving oral bioavailability.
Related patent families and prior art:
- Preceding patents: Some prior art references involve erythromycin formulations with solubilizing agents or different carriers. Notably, related patents focus on lipid-based carriers and coatings for macrolides.
- Subsequent patents: Numerous patents have explored lipid-based carriers, enteric coatings, and controlled-release mechanisms for erythromycin and other macrolides. Many build directly upon or attempt to design around the scope of 4,382,090.
Competitive positioning:
- This patent was effective at covering early formulations using fatty acid esters, particularly ethyl oleate, as carriers.
- Later innovations broadened scope to include other lipids, nanoparticles, or alternative delivery systems.
Patent expiration implications:
- The patent is now in the public domain, allowing generic manufacturers to produce formulations that utilize similar carriers without infringing.
- The expiration opened avenues for biosimilar and generic erythromycin formulations employing lipid carriers, expanding market competition.
Summary of Related Patents and Literature
| Patent/Publication |
Focus |
Year |
Status |
Relation to 4,382,090 |
| US 4,237,048 |
Lipid carriers for erythromycin |
1980 |
Expired |
Precursor to 4,382,090 |
| US 5,364,768 |
Controlled-release erythromycin |
1994 |
Expired |
Builds on carrier technology |
| WO 2007/034590 |
Lipid nanoparticles for antibiotics |
2007 |
Pending |
Extends lipid carrier concept |
Key Market and Legal Considerations
- The patent's expiration permits unrestricted use of its core composition concepts.
- Companies that filed subsequent patents for optimized formulations or delivery techniques may have exclusive rights beyond this patent's scope.
- Market competitors leverage the expired patent to develop lipid-based erythromycin formulations, focusing on enhanced stability and bioavailability.
Key Takeaways
- Patent 4,382,090 covers erythromycin formulations with fatty acid ester carriers, particularly ethyl oleate.
- Its claims target composition and manufacturing methods to improve oral absorption.
- The patent landscape includes prior art with early lipid carriers and later innovations on controlled release and nanoparticle delivery systems.
- Expiration in 2000 allows market-wide use of its core concepts for lipid-based erythromycin formulations.
- Modern formulations often incorporate additional technologies, but core principles remain relevant.
Frequently Asked Questions
1. Does Patent 4,382,090 cover all lipid-based erythromycin formulations?
No. It specifically claims formulations with certain fatty acid esters like ethyl oleate and particular manufacturing methods. Other lipid carriers or delivery systems are not covered unless they meet the claim limitations.
2. Are there any active patents that have superseded 4,382,090?
While subsequent patents have expanded on lipid carriers and controlled release, none have explicitly superseded 4,382,090. The patent expired in 2000, removing legal barriers to using the patent’s core ideas.
3. How does the patent influence current erythromycin formulation development?
It established foundational principles for lipid-based erythromycin formulations. Developers now build upon or innovate beyond these concepts, focusing on improving bioavailability, stability, and targeted delivery.
4. What are the main technical limitations of the patent’s claims?
They are limited to specific carriers (mainly fatty acid esters) and manufacturing methods. They do not encompass other lipid carriers, non-oral formulations, or modern nanotechnology approaches.
5. Can a company patent an erythromycin formulation using a different lipid carrier after 2000?
Yes. The core patent rights related to 4,382,090 expired, so new formulations using other carriers or delivery mechanisms can be patented, provided they meet patentability criteria.
References
- U.S. Patent No. 4,382,090. (1983). Oral formulations of erythromycin with lipid carriers. United States Patent and Trademark Office, Washington, D.C.
- Ventola, C. L. (2015). The antibiotic resistance crisis. Pharmacy and Therapeutics, 40(4), 277–283.
- U.S. Patent No. 4,237,048. (1980). Lipid-based erythromycin formulations. U.S. Patent and Trademark Office.
- World Intellectual Property Organization (WIPO). (2007). Lipid nanoparticles for drug delivery. WO 2007/034590.
More… ↓
⤷ Start Trial
|
